DIGITAL EVENT

Thursday, June 9, 2022 | 8.30 AM - 2.50 PM (EST)

8:30 am Online Registration

8:30 am Online Registration

9:25 am Chair’s Opening Remarks

9:25 am Chair’s Opening Remarks

Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality

Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality

9:30 am Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function

9:30 am Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function

Synopsis

  • Platelets express all the Janus kinases and several STAT proteins.
  • JAK/STAT5 pathways are activated following stimulation of glycoprotein VI with collagen in platelets.
  • Ruxolitinib and baricitinib impair platelet granule secretion, adhesion, and aggregation following stimulation with collagen.

10:00 am PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond

  • David Rosmarin MD Associate Professor, TUFTS Medical Center
  • Raj Chovatiya Assistant Professor Director, Center for Eczema and Itch Department of Dermatology, Northwestern University Feinberg School of Medicine
  • Brett King MD Associate Professor, Dermatology , Yale University School of Medicine

10:00 am PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond

  • David Rosmarin MD Associate Professor, TUFTS Medical Center
  • Raj Chovatiya Assistant Professor Director, Center for Eczema and Itch Department of Dermatology, Northwestern University Feinberg School of Medicine
  • Brett King MD Associate Professor, Dermatology , Yale University School of Medicine

Synopsis

  • Cataloguing the implications across numerous disciplines the FDA issued JAK black box warning will have just as pharma was beginning to realise the potential the JAK/STAT pathway holds.
  • Evaluating where the community sees the market potential for JAK inhibitors within the pharmaceutical industry despite the warning.
  • Discussing ways in which companies may begin marketing their JAK inhibitors whilst also debating the demand for novel therapeutic options in underserved indications, where benefit-risk calculations must take place.

10:45 am
Morning Break & Speed Networking

10:45 am
Morning Break & Speed Networking

Exploring JAK Selectivity in the Push Towards Precise Medical Approaches

Exploring JAK Selectivity in the Push Towards Precise Medical Approaches

11:15 am Balancing Benefit/Risk in the Dermatology Disease Space

  • Brett King MD Associate Professor, Dermatology , Yale University School of Medicine

11:15 am Balancing Benefit/Risk in the Dermatology Disease Space

  • Brett King MD Associate Professor, Dermatology , Yale University School of Medicine

Synopsis

  • Considering whether the black box warning will stifle innovation across the JAK inhibitor class
  • Correlating disease severity and quality of life with off-target effects of JAK inhibitors
  • Rethinking how we define the black box warning to patients

11:45 am The Journey to JAKs: First-in-Class Drugs to Treat Alopecia Areata

11:45 am The Journey to JAKs: First-in-Class Drugs to Treat Alopecia Areata

Synopsis

  • Overviewing the science that provided the rationale for JAK inhibitors in Alopecia Areata
  • Discussing biomarkers of treatment response and patient selection
  • Looking ahead to the next-generation JAK inhibitors in Alopecia Areata

12:15 pm
Lunch Break

12:15 pm
Lunch Break

Future Horizons: Looking Ahead to Best Prepare Your JAK Inhibitor Pipelines

Future Horizons: Looking Ahead to Best Prepare Your JAK Inhibitor Pipelines

1:15 pm Revolutionizing Translational Modeling with 3D Technology

1:15 pm Revolutionizing Translational Modeling with 3D Technology

Synopsis

  • Introducing the capabilities of the Tissue Bioprinting Lab at NCATS
  • Championing 3D vascularized barrier tissue models with relevant disease models
  • Relaying the multitude of translational applications with JAK inhibitors

1:45 pm Novel Strategies of Localized Drug Delivery to Re-Think the Application of JAK inhibitors

1:45 pm Novel Strategies of Localized Drug Delivery to Re-Think the Application of JAK inhibitors

Synopsis

  • Developing a biocompatible lipid nanoformulation that encapsulate JAK inhibitors to achieve preferential targeting of the gut immune system following oral administration.
  • Exploring a novel potential for JAK inhibitors as immunotherapeutics, rather than immunosuppressive drugs, in the treatment of autoimmunity and transplant rejection.
  • Developing injectable hydrogels for localized and controlled release of JAK inhibitors and future advances.

2:15 pm FDA Perspective on JAK Inhibitor Development & Dermatologic Disorders

2:15 pm FDA Perspective on JAK Inhibitor Development & Dermatologic Disorders

Synopsis

  • Considering what clinical endpoints the FDA will accept across multiple disciplines within JAK inhibitor drug development to accelerate delivery to market
  • Q&A Time: An extended 15 minute session post presentation to alleviate all JAK inhibitor pipeline queries and save labor downstream

2:45 pm Chairs Closing Remarks

2:45 pm Chairs Closing Remarks

2:50 pm END OF CONFERENCE

2:50 pm END OF CONFERENCE